Trial Profile
A Phase I and Pharmacodynamic Study of Proteasome Inhibitor, PS-341, in Combination With Doxorubicin in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2012
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2005 New trial record.